Suzhou Basecare Medical Corporation Limited (2170.HK)
- Previous Close
2.900 - Open
2.900 - Bid 2.850 x --
- Ask 2.890 x --
- Day's Range
2.900 - 2.900 - 52 Week Range
1.290 - 4.450 - Volume
500 - Avg. Volume
161,374 - Market Cap (intraday)
793.225M - Beta (5Y Monthly) 0.17
- PE Ratio (TTM)
-- - EPS (TTM)
-0.970 - Earnings Date Mar 28, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
2.93
Suzhou Basecare Medical Corporation Limited, an investment holding company provides genetic testing solutions for assisted human reproduction in the People's Republic of China and Australia. The company offers genetic test kit products, which include pre-implantation genetic test kits, such as PGT-A to detect aneuploidy; PGT-M to detect single-gene or monogenic defects in pre-implantation embryos; and PGT-SR kits to detect chromosome structural rearrangements, which are common causes of recurrent miscarriage. It also offers liquid nitrogen storage dewar, Cryopreservation system, and sperm quality analyzer; universal kits for sequencing effects; sample preservation solution; and nucleic acid purification and DNA extraction kits. The company also engages in the research, development, manufacture, and sale of testing kits, testing devices, and instruments. In addition, it provides marketing services; and engages in the research and development of software for testing devices and instruments. The company serves hospitals and reproductive clinics. Suzhou Basecare Medical Corporation Limited was incorporated in 2010 and is headquartered in Suzhou, China.
www.basecare.cnRecent News: 2170.HK
View MorePerformance Overview: 2170.HK
Trailing total returns as of 5/15/2025, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 2170.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 2170.HK
View MoreValuation Measures
Market Cap
793.23M
Enterprise Value
407.99M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.45
Price/Book (mrq)
0.64
Enterprise Value/Revenue
1.26
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-79.25%
Return on Assets (ttm)
-9.38%
Return on Equity (ttm)
-18.68%
Revenue (ttm)
299.11M
Net Income Avi to Common (ttm)
-237.03M
Diluted EPS (ttm)
-0.970
Balance Sheet and Cash Flow
Total Cash (mrq)
687.16M
Total Debt/Equity (mrq)
28.76%
Levered Free Cash Flow (ttm)
-267.63M